Zachary Simmons

List of Publications by Year
in descending order

99 papers	4,642 citations	117453 34 h-index	114278 63 g-index
106 all docs	106 docs citations	106 times ranked	5697 citing authors

#	Article	IF	Citations
1	An online non-meditative mindfulness intervention for people with ALS and their caregivers: a randomized controlled trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 116-127.	1.1	12
2	Laryngospasm: A frequently underrecognized symptom in amyotrophic lateral sclerosis. Muscle and Nerve, 2022, , .	1.0	0
3	Ten years of riluzole use in a tertiary ALS clinic. Muscle and Nerve, 2022, 65, 659-666.	1.0	2
4	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 287-299.	1.1	42
5	Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 186.	4.5	79
6	Palliative specialists for patients with <scp>ALS</scp>: Making best use of a limited resource. Muscle and Nerve, 2021, 63, 790-792.	1.0	2
7	Inertial sensing of step kinematics in ambulatory patients with ALS and related motor neuron diseases. Journal of Medical Engineering and Technology, 2021, 45, 486-493.	0.8	6
8	Tocilizumab is safe and tolerable and reduces <scp>C</scp>â€reactive protein concentrations in the plasma and cerebrospinal fluid of <scp>ALS</scp> patients. Muscle and Nerve, 2021, 64, 309-320.	1.0	27
9	Ethical Considerations in Dementia Diagnosis and Care. Neurology, 2021, 97, 80-89.	1.5	12
10	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	4.5	46
11	Physicianâ€hastened death in <scp>California</scp> for patients with amyotrophic lateral sclerosis: Part of a bigger picture. Muscle and Nerve, 2021, 64, 381-384.	1.0	1
12	Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. Muscle and Nerve, 2021, 63, 371-383.	1.0	13
13	Primary lateral sclerosis (PLS) functional rating scale: PLSâ€specific clinimetric scale. Muscle and Nerve, 2020, 61, 163-172.	1.0	17
14	<scp>COVIDâ€19â€“associated GuillainâBarrÃ©</scp> syndrome: The early pandemic experience. Muscle and Nerve, 2020, 62, 485-491.	1.0	196
15	Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials. Muscle and Nerve, 2020, 62, 321-326.	1.0	24
16	Understanding the needs of people with ALS: a national survey of patients and caregivers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 355-363.	1.1	27
17	Telemedicine for the Care of Neuromuscular Disorders. Current Treatment Options in Neurology, 2020, 22, 1.	0.7	2
18	Terminology in Neuromuscular Electrodiagnostic Medicine and Ultrasound: Time for an Update. Muscle and Nerve, 2020, 62, 1-1.	1.0	2

#	Article	IF	Citations
19	In defense of the AAN position on lawful physician-hastened death. Neurology, 2020, 94, 641-643.	1.5	2
20	What's New at Muscle & Nerve?. Muscle and Nerve, 2020, 62, 152-153.	1.0	0
21	The Use of Telehealth to Enhance Care in ALS and other Neuromuscular Disorders. Muscle and Nerve, 2020, 61, 682-691.	1.0	39
22	Amyotrophic lateral sclerosis care and research in the United States during the <scp>COVID</scp>â€19 pandemic: Challenges and opportunities. Muscle and Nerve, 2020, 62, 182-186.	1.0	42
23	Neurophysiological features of primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 11-17.	1.1	11
24	Primary lateral sclerosis: consensus diagnostic criteria. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 373-377.	0.9	118
25	Telemedicine to innovate amyotrophic lateral sclerosis multidisciplinary care: The time has come. Muscle and Nerve, 2019, 59, 3-5.	1.0	25
26	Changing with the times. Muscle and Nerve, 2019, 60, 343-344.	1.0	0
27	ULTRASOUND IN THE DIAGNOSIS AND MONITORING OF AMYOTROPHIC LATERAL SCLEROSIS: A REVIEW. Muscle and Nerve, 2019, 60, 114-123.	1.0	43
28	Evaluation of remote pulmonary function testing in motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 348-355.	1.1	28
29	Lawful physician-hastened death. Neurology, 2018, 90, 420-422.	1.5	19
30	Goodbye to neuromuscular images. Muscle and Nerve, 2018, 57, 167-167.	1.0	0
31	Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 167-172.	1.1	11
32	Hydration measured by doubly labeled water in ALS and its effects on survival. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 220-231.	1.1	8
33	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	3.8	517
34	Symptom management in amyotrophic lateral sclerosis: We can do better. Muscle and Nerve, 2018, 57, 1-3.	1.0	5
35	Guidelines for Authors: A view from the Editor's desk. Muscle and Nerve, 2018, 59, 147-148.	1.0	0
36	Ethical Considerations in Neurogenetic Testing. Seminars in Neurology, 2018, 38, 505-514.	0.5	5

#	Article	IF	Citations
37	Amyotrophic lateral sclerosisâ€“specific quality of lifeâ€“short form (ALSSQOLâ€SF): A brief, reliable, and valid version of the ALSSQOLâ€R. Muscle and Nerve, 2018, 58, 646-654.	1.0	21
38	Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism. ELife, 2018, 7, .	2.8	53
39	So many submissionsâ€¦so little space. Muscle and Nerve, 2017, 55, 299-300.	1.0	2
40	Article submission: The scope of muscle & nerve. Muscle and Nerve, 2017, 55, 615-616.	1.0	1
41	Neuromuscular images: A picture can be worth more than a thousand words. Muscle and Nerve, 2017, 56, 1-1.	1.0	0
42	A new editor: Changes in Muscle & Nerve. Muscle and Nerve, 2017, 55, 1-2.	1.0	0
43	Amyotrophic lateral sclerosis. Nature Reviews Disease Primers, 2017, 3, 17071.	18.1	885
44	Expansion of C9ORF72 in amyotrophic lateral sclerosis correlates with brain-computer interface performance. Scientific Reports, 2017, 7, 8875.	1.6	1
45	Incorporation of telehealth into a multidisciplinary ALS Clinic: feasibility and acceptability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 555-561.	1.1	67
46	Advance care planning for patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 388-396.	1.1	26
47	The P300 â€˜faceâ€™ speller is resistant to cognitive decline in ALS. Brain-Computer Interfaces, 2017, 4, 225-235.	0.9	8
48	Statins accelerate disease progression and shorten survival in SOD1^{G93A} mice. Muscle and Nerve, 2016, 54, 284-291.	1.0	23
49	Muscle & nervejoins the â€œApp Worldâ€• Muscle and Nerve, 2016, 53, 1-2.	1.0	1
50	Ethical issues in the evaluation of adults with suspected genetic neuromuscular disorders. Muscle and Nerve, 2016, 54, 997-1006.	1.0	4
51	Primary Lateral Sclerosis and Early Upper Motor Neuron Disease. Journal of Clinical Neuromuscular Disease, 2016, 17, 99-105.	0.3	17
52	A Qualitative Study of Multidisciplinary ALS Clinic Use in the United States. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 55-61.	1.1	50
53	The role of mental health and self-efficacy in the pain experience of patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 206-212.	1.1	15
54	A randomized trial of mexiletine in ALS. Neurology, 2016, 86, 1474-1481.	1.5	72

#	Article	IF	Citations
55	Patient-reported problematic symptoms in an ALS treatment trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 198-205.	1.1	37
56	Verbal communication impacts quality of life in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 179-183.	1.1	49
57	Compliance with recommendations made in a multidisciplinary ALS clinic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 30-37.	1.1	9
58	Pain in amyotrophic lateral sclerosis: Patient and physician perspectives and practices. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 21-29.	1.1	31
59	Isaacs syndrome: A review. Muscle and Nerve, 2015, 52, 5-12.	1.0	88
60	The potential of psychological interventions to improve quality of life and mood in muscle disorders. Muscle and Nerve, 2015, 52, 131-136.	1.0	35
61	Patient-Perceived Outcomes and Quality of Life in ALS. Neurotherapeutics, 2015, 12, 394-402.	2.1	63
62	Multidisciplinary ALS clinics in the USA: A comparison of those who attend and those who do not. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 196-201.	1.1	17
63	Relationship of creatine kinase to body composition, disease state, and longevity in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 473-477.	1.1	23
64	Loss and well-being in ALS: A different perspective on the challenge. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 163-164.	1.1	1
65	H63D HFE genotype accelerates disease progression in animal models of amyotrophic lateral sclerosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2413-2426.	1.8	26
66	Electrodiagnosis of Brachial Plexopathies and Proximal Upper Extremity Neuropathies. Physical Medicine and Rehabilitation Clinics of North America, 2013, 24, 13-32.	0.7	20
67	Rehabilitation of motor neuron disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 110, 483-498.	1.0	15
68	Pseudobulbar affect: prevalence and management. Therapeutics and Clinical Risk Management, 2013, 9, 483.	0.9	70
69	Non-invasive ventilation and gastrostomy may not impact overall quality of life in patients with ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 55-58.	2.3	23
70	What's in the Literature?. Journal of Clinical Neuromuscular Disease, 2012, 13, 162-167.	0.3	0
71	VALUESâ€: a national multicenter study of regional and gender differences in frontotemporal disease in amyotrophic lateral sclerosis. Neurodegenerative Disease Management, 2012, 2, 325-336.	1.2	4
72	Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle and Nerve, 2012, 46, 9-25.	1.0	96

#	Article	IF	Citations
73	Psychological health in patients with ALS is maintained as physical function declines. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 290-296.	2.3	37
74	Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 413-418.	0.9	95
75	What's in the Literature?. Journal of Clinical Neuromuscular Disease, 2010, 11, 223-228.	0.3	1
76	The Neuromuscular Manifestations of Amyloidosis. Journal of Clinical Neuromuscular Disease, 2010, 11, 145-157.	0.3	31
77	Psychological morbidity in ALS: The importance of psychological assessment beyond depression alone. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 351-358.	2.3	32
78	Problem solving skills predict quality of life and psychological morbidity in ALS caregivers. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 147-153.	2.3	35
79	Can we eliminate placebo in ALS clinical Trials?. Muscle and Nerve, 2009, 39, 861-865.	1.0	8
80	The SEIQoL-DW for assessing quality of life in ALS: Strengths and limitations. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 456-462.	2.3	44
81	Respiratory systems abnormalities and clinical milestones for patients with amyotrophic lateral sclerosis with emphasis upon survival. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 36-41.	2.3	47
82	A rapid screening battery to identify frontal dysfunction in patients with ALS. Neurology, 2006, 67, 2070-2072.	1.5	55
83	Management Strategies for Patients With Amyotrophic Lateral Sclerosis From Diagnosis Through Death. Neurologist, 2005, 11, 257-270.	0.4	92
84	Factors supporting quality of life over time for individuals with amyotrophic lateral sclerosis: the role of positive self-perception and religiosity. Annals of Behavioral Medicine, 2004, 28, 119-125.	1.7	44
85	Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. Journal of the Neurological Sciences, 2004, 227, 27-33.	0.3	114
86	Muscle biopsy in the evaluation of patients with modestly elevated creatine kinase levels. Muscle and Nerve, 2003, 27, 242-244.	1.0	39
87	Religiousness is related to quality of life in patients with ALS. Neurology, 2003, 60, 1527-1529.	1.5	51
88	Sporadic Inclusion Body Myositis and Hereditary Inclusion Body Myopathy. Journal of Clinical Neuromuscular Disease, 2002, 3, 122-132.	0.3	12
89	Update on diabetic neuropathy. Current Opinion in Neurology, 2002, 15, 595-603.	1.8	99
90	Hypothyroid myopathy with a strikingly elevated serum creatine kinase level. Muscle and Nerve, 2002, 26, 141-144.	1.0	62

#	Article	IF	Citations
91	Reproducibility of motor unit number estimation in individual subjects. Muscle and Nerve, 2001, 24, 467-473.	1.0	35
92	Localized hypertrophic neuropathy: Magnetic resonance imaging findings and long-term follow-up. , 1999, 22, 28-36.		59
93	Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking DMAHP gene. Nature Genetics, 1997, 16, 407-409.	9.4	205
94	Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. , 1997, 20, 1008-1015.		59
95	Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. , 1997, 20, 1569-1575.		68
96	Variation of calculated ulnar motor conduction velocity across the elbow with body mass index. , 1997, 20, 1607-1608.		10
97	Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. Muscle and Nerve, 1997, 20, 1008-1015.	1.0	3
98	Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis. Journal of the Neurological Sciences, 1993, 120, 60-63.	0.3	67
99	Treatment of Diabetic Neuropathy. , 0, , 555-576.		1